【作者】 宋万新； 李煜； 谢爽；

【Author】 Song Wan-Xin Li Yu Xie Shuang Nanyang Tumor Hospital, Nanyang, 473061

【机构】 南阳市肿瘤医院；

【摘要】 目的:评价肝动脉化疗栓塞术,门脉化疗术联合免疫治疗原发性肝癌的疗效和不良反应。方法: 4 4例原发性肝癌患者无行肝动脉化疗栓塞术(免疫药物),三天后在B超下行门脉穿刺置管,行门脉化疗。结果:总有效率45．5％(20／44),1、2、3年生存率分别为72．7％、45．5％、27．3％,KPS评分平均增加3 0分,明显优于文献报道。不良反应:胃肠道反应I°64例次,II°1 8例次,骨髓抑制:I°66 例次,II°32例次,III°14例次。轻度右上腹困痛不适,发热。无严重心、肺、胃损伤。无肝功能衰竭等严重并发症。结论:肝动脉化疗栓塞术,门脉化疗术联合免疫治疗原发性肝癌效果优于单纯肝动脉化疗栓塞术, 生活质量提高,生存期延长。更多还原

【Abstract】 Objective: To evalute curative effect and toxicity of liver arterial chemoembolization and portal vein chemotherapy treat prionary HCC associated with immune . Methods: 44 patients of primary liver cancer don’ t use liver arterial chemoembolization (immune medicine), after three days, use portal vien transcatheter with B supersonic. Results: All of efficiency was 45.5% (20/44), 1- , 2- and 3-year survival rates were 72.7%, 45.5%, 27.3%, respectively. KPS grade average added 30, better-than report news. Toxicity : 64 cases of gastrointestinal response I ° , 18 cases of response II ° , Myelosuppression : 66 cases of I° ,32 cases of II° ,14 cases of III° . Mide abdominal pain, fever. Conclusion: This technique effect better than single liver arterial chemoembolization to improve quality of living ,to prolong existent time.更多还原